Main Article Content


Systemic lupus erythematous is a autoimmune disease which is a chronic multisystemic heterogenous disease caused by self-destruction of system by production of autoantibodies due to self-antigens.  Novel therapeutic approaches are necessary to treat SLE despite tremendous advancements in therapeutic alternatives and greater understanding of the pathophysiology. An innovative approach that may significantly improve the treatment of serious diseases is immune system modulation based on nanotechnology. Therapeutic delivery may be enhanced by nanoparticle-based delivery systems that target inflammatory tissue or a particular cell for drug administration. Non-steroidal anti-inflammatory drugs, antimalarials, corticosteroids, and cytotoxic/immunosuppressive drugs have all been used to treat SLE in the past, but perhaps more recently, the focus has focused on developing biological agents that can inhibit autoreactive B cells, prevent cytokine signalling, and promote the growth of regulatory T cells. In this review article is being discussed about new technical approaches to treat the systemic lupus erythematous.  In 2020, the U.S. market for drugs for Systemic lupus erythematosus (SLE) is anticipated to be worth $50.8 million. With a predicted market size of US$46.9 million by 2027 and a CAGR of 5.7% from 2020 to 2027, China, the second-largest economy in the world, is expected to be the fastest-growing region.


Systemic lupus erythematous, autoimmune disease, B cells, nanotechnology

Article Details